Factors associated with mortality in patients with COVID-19. A quantitative evidence synthesis of clinical and laboratory dataThe COVID-19 pandemic caused by the severe acute respiratory coronavirus 2 (SARS-CoV-2) has become a serious challenge for health systems worldwide. Despite the favorable clinical course for most cases, a mortality rate of 30-70% is expected for COVID-19 patients treated on intensive care unit (ICU) [1]. Reports have shown an increased risk of death for older patients with existing comorbidities and potential biomarkers associated with severity for COVID-19 patients [2,3].Because of the complexity and the limited evidence on the pathogenesis of COVID-19, the management of critically ill patients has been challenging. Multiple recent studies have provided valuable clinical and laboratory features of hospitalized patients with COVID-19, but in many of them the information is not complete and there is a potential for overlapping data. Therefore, findings from a comprehensive systematic review can help physicians to understand the disease and make decisions for critically ill patients. In this study, we performed a quantitative evidence synthesis of clinical and laboratory factors associated with mortality in patients with COVID-19.We searched the peer-reviewed (PubMed, Web of Science, Scopus, Embase) and gray (Google Scholar, bioRxiv, medRxiv) literature to identify studies comparing clinical data, laboratory parameters (hematological, biochemical, inflammatory markers, coagulation factors, and blood gas analysis) and complications between non-survivors and survivors of COVID-19. We included only studies providing clinical data and at least one of the laboratory parameters previously mentioned. We excluded publications with potential overlapping reports, and studies from which data extraction was not possible. In case of potential overlapping data, we selected the study with most complete information.Reports were screened in two stages: screening of titles and abstracts followed by the retrieval and screening of full-text articles. Searches were performed from January 1, 2020 up to April 06, 2020, without language restrictions. The reference lists of all eligible studies and reviews were also evaluated to identify additional studies for inclusion. The following search terms were used: "COVID-19″, "severe acute respiratory syndrome coronavirus 2″, "SARS-CoV-2″, "2019-nCoV", "coronavirus" and "coronaviruses".Data from publications were extracted by two authors and crosschecked for accuracy. Our outcome of interest was in-hospital death. Clinical data, laboratory parameters, and complications were considered predictor variables. Effect sizes were reported as mean difference (MD) or standardized mean difference (SMD) for continuous variables and risk ratio (RR) for dichotomous variables with 95% confidence intervals (CI). Not all studies reported data on all predictor variables, and the pooled analysis was estimated from the data available for each variable. A random-effects model was used to poo...

No abstract

Our results suggest that farmers in this semiarid area have a high risk of lip cancer and indicate the need for health public programs in the early detection of AC and education to teach the population about precautions to be taken during sun exposure.

A rapid systematic review was carried out to evaluate the current evidence related to the presence of SARS-CoV-2 in breast milk from pregnant women with COVID-19. Eight studies analyzing the presence of SARS-CoV-2 RNA in the breast milk of 24 pregnant women with COVID-19 during the third trimester of pregnancy were found. All patients had fever and/or symptoms of acute respiratory illness and chest computed tomography images indicative of COVID-19 pneumonia. Most pregnant women had cesarean delivery (91.7%) and two neonates had low birthweight (< 2 500 g). Biological samples collected immediately after birth from upper respiratory tract (throat or nasopharyngeal) of neonates and placental tissues showed negative results for the presence SARS-CoV-2 by RT-PCR test. No breast milk samples were positive for SARS-CoV-2 and, to date, there is no evidence on the presence of SARS-CoV-2 in breast milk of pregnant women with COVID-19. However, data are still limited and breastfeeding of women with COVID-19 remains a controversial issue. There are no restrictions on the use of milk from a human breast milk bank.

Context:Focal fibrous hyperplasia, also known as irritation or traumatic fibroma, is a reactive, inflammatory hyperplastic lesion of the connective tissue.Aim:The aim of this study is to perform a retrospective study of a focal fibrous hyperplasia of 18 years.Materials and Methods:We retrospectively reviewed 193 cases of focal fibrous hyperplasia of the oral cavity from the medical and histological reports of the Department of Oral Pathology, Pernambuco University, Brazil, during the period between January 1992 and December 2009.Settings and Design:Data with regard to age, gender, location, size of the lesion (equal to or less than 1 cm, between 1 and 2 cm and greater than 2 cm), pain, history of trauma, treatment, length of follow-up (from diagnosis to release or last review) and recurrence, were collected.Results:The most commonly affected site was the buccal mucosa (n = 119, 61.7%). Almost two-thirds of the cases were concentrated from the second to the fifth decade of life. Females were more affected than men and a history of trauma was related by 90.7% of the patients. Two recurrences were notified (1.0%).Conclusion:Further studies are needed on the distribution of the lesion in different ethnic and geographical populations. The influence of sex hormones on the development of focal fibrous hyperplasia must be clarified.

No abstract

No abstract

No abstract